27389831|t|Longitudinal live imaging of retinal α-synuclein :: GFP deposits in a transgenic mouse model of Parkinson's Disease / Dementia with Lewy Bodies
27389831|a|Abnormal α-synuclein (α-syn) accumulation in the CNS may underlie neuronal cell and synaptic dysfunction leading to motor and cognitive deficits in synucleinopathies including Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB). Multiple groups demonstrated α-syn accumulation in CNS accessory structures, including the eyes and olfactory terminals, as well as in peripheral organs of Parkinsonian patients. Retinal imaging studies of mice overexpressing fused α-syn :: GFP were conducted to evaluate the presence and progression of retinal pathology in a PD / DLB transgenic mouse model. Bright-field image retinal maps and fluorescent images were acquired at 1-month intervals for 3 months. Retinal imaging revealed the accumulation of GFP -tagged α-syn in retinal ganglion cell layer and in the edges of arterial blood vessels in the transgenic mice. Double labeling studies confirmed that the α-syn :: GFP -positive cells were retinal ganglion cells containing α-syn. Accumulation of α-syn persisted in the same cells and increased with age. Accumulation of α-syn :: GFP was reduced by immunization with single chain antibodies against α-syn. In conclusion, longitudinal live imaging of the retina in the PDGF - α-syn :: GFP mice might represent a useful, non-invasive tool to monitor the fate of α-syn accumulation in the CNS and to evaluate the therapeutic effects of compounds targeting α-syn.
27389831	0	25	Longitudinal live imaging	T060	C1881134
27389831	29	36	retinal	T023	C0035298
27389831	37	48	α-synuclein	T116,T123	C0285890
27389831	52	55	GFP	T116,T130	C0120285
27389831	56	64	deposits	T020	C0235972
27389831	70	92	transgenic mouse model	T015	C0025936
27389831	96	115	Parkinson's Disease	T047	C0030567
27389831	118	143	Dementia with Lewy Bodies	T047	C0752347
27389831	144	152	Abnormal	T116,T123	C0311448
27389831	153	164	α-synuclein	T116,T123	C0285890
27389831	166	171	α-syn	T116,T123	C0285890
27389831	173	185	accumulation	T033	C4055506
27389831	193	196	CNS	T022	C3714787
27389831	210	223	neuronal cell	T025	C0027882
27389831	228	236	synaptic	T030	C0039062
27389831	237	248	dysfunction	T046	C0277785
27389831	260	265	motor	T033	C0521654
27389831	270	288	cognitive deficits	T033	C3277798
27389831	292	309	synucleinopathies	T047	C0524851
27389831	320	339	Parkinson's disease	T047	C0030567
27389831	341	343	PD	T047	C0030567
27389831	349	374	Dementia with Lewy Bodies	T047	C0752347
27389831	376	379	DLB	T047	C0752347
27389831	411	416	α-syn	T116,T123	C0285890
27389831	417	429	accumulation	T033	C4055506
27389831	433	436	CNS	T022	C3714787
27389831	437	457	accessory structures	T023	C0000905
27389831	473	477	eyes	T023	C0015392
27389831	482	501	olfactory terminals	T023	C0028938
27389831	517	527	peripheral	T082	C0205100
27389831	528	534	organs	T023	C0178784
27389831	538	550	Parkinsonian	T047	C0242422
27389831	551	559	patients	T101	C0030705
27389831	561	568	Retinal	T023	C0035298
27389831	569	584	imaging studies	T060	C1881134
27389831	588	592	mice	T015	C0025936
27389831	593	607	overexpressing	T045	C1514559
27389831	614	619	α-syn	T116,T123	C0285890
27389831	623	626	GFP	T116,T130	C0120285
27389831	645	653	evaluate	T058	C0220825
27389831	671	682	progression	T169	C0449258
27389831	686	693	retinal	T023	C0035298
27389831	694	703	pathology	T091	C0030664
27389831	709	711	PD	T047	C0030567
27389831	714	717	DLB	T047	C0752347
27389831	718	740	transgenic mouse model	T015	C0025936
27389831	742	760	Bright-field image	T059	C0441073
27389831	761	773	retinal maps	T070	C0237660
27389831	778	796	fluorescent images	T060	C0430876
27389831	846	853	Retinal	T023	C0035298
27389831	854	861	imaging	T060	C1881134
27389831	875	887	accumulation	T033	C4055506
27389831	891	894	GFP	T116,T130	C0120285
27389831	903	908	α-syn	T116,T123	C0285890
27389831	912	939	retinal ganglion cell layer	T025	C0035316
27389831	960	968	arterial	T082	C0221464
27389831	969	982	blood vessels	T023	C0005847
27389831	990	1005	transgenic mice	T015	C0025936
27389831	1007	1030	Double labeling studies	T062	C0242481
27389831	1050	1055	α-syn	T116,T123	C0285890
27389831	1059	1062	GFP	T116,T130	C0120285
27389831	1073	1078	cells	T025	C0007634
27389831	1084	1106	retinal ganglion cells	T025	C0035316
27389831	1118	1123	α-syn	T116,T123	C0285890
27389831	1125	1137	Accumulation	T033	C4055506
27389831	1141	1146	α-syn	T116,T123	C0285890
27389831	1169	1174	cells	T025	C0007634
27389831	1194	1197	age	T032	C0001779
27389831	1199	1211	Accumulation	T033	C4055506
27389831	1215	1220	α-syn	T116,T123	C0285890
27389831	1224	1227	GFP	T116,T130	C0120285
27389831	1243	1255	immunization	T061	C0020971
27389831	1261	1284	single chain antibodies	T129	C1883036
27389831	1293	1298	α-syn	T116,T123	C0285890
27389831	1315	1340	longitudinal live imaging	T060	C1881134
27389831	1348	1354	retina	T023	C0035298
27389831	1362	1366	PDGF	T116,T123	C0032200
27389831	1369	1374	α-syn	T116,T123	C0285890
27389831	1378	1381	GFP	T116,T130	C0120285
27389831	1382	1386	mice	T015	C0025936
27389831	1413	1425	non-invasive	T169	C0205303
27389831	1454	1459	α-syn	T116,T123	C0285890
27389831	1460	1472	accumulation	T033	C4055506
27389831	1480	1483	CNS	T022	C3714787
27389831	1491	1499	evaluate	T058	C0220825
27389831	1504	1523	therapeutic effects	T201	C1527144
27389831	1527	1536	compounds	T121	C1254351
27389831	1537	1546	targeting	T169	C1521840
27389831	1547	1552	α-syn	T116,T123	C0285890